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Abstract
Background: Epicardial injection of heart-derived cell products is safe and
effective post-myocardial infarction (MI), but clinically-translatable transendocardial
injection has never been evaluated. We sought to assess the feasibility, safety and
efficacy of percutaneous transendocardial injection of heart-derived cells in porcine
chronic ischemic cardiomyopathy.
Methods and Results: We studied a total of 89 minipigs; 63 completed the
specified protocols. After NOGA-guided transendocardial injection, we quantified
engraftment of escalating doses of allogeneic cardiospheres or cardiosphere-
derived cells in minipigs (n522) post-MI. Next, a dose-ranging, blinded,
randomized, placebo-controlled (‘‘dose optimization’’) study of transendocardial
injection of the better-engrafting product was performed in infarcted minipigs
(n516). Finally, the superior product and dose (150 million cardiospheres) were
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tested in a blinded, randomized, placebo-controlled (‘‘pivotal’’) study (n522).
Contrast-enhanced cardiac MRI revealed that all cardiosphere doses preserved
systolic function and attenuated remodeling. The maximum feasible dose (150
million cells) was most effective in reducing scar size, increasing viable
myocardium and improving ejection fraction. In the pivotal study, eight weeks post-
injection, histopathology demonstrated no excess inflammation, and no myocyte
hypertrophy, in treated minipigs versus controls. No alloreactive donor-specific
antibodies developed over time. MRI showed reduced scar size, increased viable
mass, and attenuation of cardiac dilatation with no effect on ejection fraction in the
treated group compared to placebo.
Conclusions: Dose-optimized injection of allogeneic cardiospheres is safe,
decreases scar size, increases viable myocardium, and attenuates cardiac
dilatation in porcine chronic ischemic cardiomyopathy. The decreases in scar size,
mirrored by increases in viable myocardium, are consistent with therapeutic
regeneration.
Introduction
Approximately six million Americans [1] and 23 million people worldwide [2]
suffer from chronic heart failure. While traditional therapies aim at attenuating
disease progression, regenerative cell therapy seeks to reverse heart failure by
regrowing healthy working myocardium. To that end, numerous cell types and
delivery methods have been studied [3, 4, 5]. Cells derived from the heart are
particularly attractive; intracoronary infusion of autologous cardiosphere-derived
cells (CDCs) [6, 7] or c-kit+ heart-derived cells [8] has shown promising results in
patients with post-ischemic ventricular dysfunction (although doubt has been cast
regarding data presented in SCIPIO, the c-kit+ cell clinical study) [9]. While
intracoronary delivery is safe and convenient, cell retention is low [10]. Since
increased cellular retention has been associated with greater long-term benefits on
cardiac function both in animal models [11, 12, 13] and in humans [14, 15], there
is good reason to believe that development of delivery methods with better
engraftment might enhance the efficacy of cell therapy, especially in the setting of
chronic ischemic cardiomyopathy, where local homing signals are reduced [16].
Preclinical and clinical studies have shown that intramyocardial (IM) cell delivery
leads to greater cardiac engraftment compared to intracoronary delivery
[15, 17, 18, 19, 20, 21], although agreement on this point is not universal
[22, 23, 24]. Intramyocardial injection also enables the use of cardiospheres (CSps,
three-dimensional spherical clusters of heart-derived cells), which are more
efficacious than CDCs when both human products are delivered IM in
immunodeficient mice with acute MI [25]. In pigs, open-chest epicardial injection
of CDCs and CSps is safe and effective post-MI [26]. However, clinically-
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translatable transendocardial injection of heart-derived cell products has never
been reported.
We initially sought to optimize dosing and delivery protocols for transendo-
cardial injection of heart-derived cell products, and then to test the optimized
process in chronic porcine ischemic cardiomyopathy. First, we compared 24-hour
engraftment of allogeneic CSps and CDCs using NOGA-guided transendocardial
injection. Second, we performed a dose-ranging study of the better-engrafting cell
product. Finally, we performed a pivotal, randomized, blinded, placebo-
controlled study to investigate if dose-optimized transendocardial injection of
heart-derived cells is safe and effective in a porcine model of chronic ischemic
cardiomyopathy. Our aims were successfully achieved and this method has proved
to be safe and effective.
Methods
All animal studies were performed in an American Association for Accreditation
of Laboratory Animal Care accredited facility with approval from the Institutional
Animal Care and Use Committee of the Cedars-Sinai Medical Center. All
procedures were performed using full analgesia and anesthesia, when appropriate,
and all efforts were made to eliminate suffering.
Three separate experimental protocols were performed, as depicted schema-
tically in Figure 1. A total of 89 pigs were studied: 22 completed the engraftment
study (Figure 1A); 16 completed the dose optimization study (Figure 1B); 22
completed the pivotal study (Figure 1C); 26 were excluded per protocol for
procedural mortality or high ejection fraction; and 3 were used for allosensitiza-
tion protocols. Three pigs served as heart donors for derivation of cell products.
Engraftment study
Cell culture
A freshly-explanted heart from one male farm pig was minced into multiple
,500 mm3 pieces and digested with collagenase IV (Sigma Aldrich, St. Louis,
MO). These explants were plated onto fibronectin (BD Biosciences, San Jose,
CA)-coated dishes with cardiac explant medium (IMDM [Invitrogen, Carlsbad,
CA], 20% FBS, 1% penicillin-streptomycin, 1% L-glutamine, 0.1 mM 2-
mercaptoethanol) and expanded at 37 C̊ for two weeks. The outgrowth of
adherent cells was harvested and re-plated into poly-D-lysine (BD, Franklin Lakes,
NJ)-coated wells. Within three days, the majority of the cells gave rise to three-
dimensional, free-floating clusters of cells termed primary CSps. Free-floating
primary CSps were collected and plated onto fibronectin-coated dishes. The
primary CSps adhered and flattened to form a monolayer of CDCs [7, 27], which
were transduced with an adenovirus expressing the firefly luciferase gene. For
animals receiving luciferase-labeled CDCs, cells were harvested on the day of
injection and injected at this stage. For animals receiving luciferase-labeled CSps,
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CDCs were re-plated into poly-D-lysine-coated wells to form secondary CSps.
Secondary CSps were harvested and filtered immediately prior to injection with a
160 mm nylon net filter (Millipore, Billerica, MA). The maximum feasible dose of
CSps was determined to be 100–200 million isolated cell equivalents (ICEs)
delivered as CSps (see Results).
Induction of MI and transendocardial cell injection
Thirty-three adult Yucatan minipigs (15¡5 months) weighing 52¡9 kg were
studied. A porcine model of post-MI ischemic cardiomyopathy was used [28, 29].
On day 0, animals were premedicated with ketamine 20 mg/kg IM, atropine
0.05 mg/kg IM, and acepromazine 0.25 mg/kg IM. They were induced with
propofol 2–4 mg/kg IV to effect, intubated, and maintained on isoflurane 2–3%.
Amiodarone (10 mg/kg IV loading dose, then 0.5 mg/kg IV PRN) and lidocaine
Figure 1. Schematic depiction of the timeline for three experimental protocols. A) Engraftment Study. B)
Dose Optimization Study. C) Pivotal Study. Red lines indicate timepoints of blood draws.
doi:10.1371/journal.pone.0113805.g001
Transendocardial Allogeneic Cardiospheres in Pigs
PLOS ONE | DOI:10.1371/journal.pone.0113805 December 2, 2014 4 / 29
(0.03 mg/kg/min CRI) were given to prevent/treat ventricular arrhythmias.
Heparin 100 IU/kg IV was given for anticoagulation. A coronary dilation catheter
(Trek OTW 2–3 mm, Abbott Vascular, Santa Clara, CA) was inflated in the mid-
LAD (immediately after the 1st diagonal branch), providing 100% occlusion for
2.5 hours. Post-operative oxymorphone 0.15 mg/kg IM BID PRN and carprofen
4 mg/kg PO q24h PRN were administered for analgesia.
On day 28, animals were re-anesthetized using the same protocol and drug
regimen. Pigs were randomized to receive luciferase-labeled cells: a) high-dose
CSps (10 million ICEs); b) low-dose CSps (5 million ICEs); c) high-dose CDCs
(10 million CDCs); d) low-dose CDCs (5 million CDCs); and e) maximum
feasible dose CSps (100–200 million ICEs). Randomization for all arms of the
study was performed by the cell manufacturing laboratory staff, with the
remaining staff blinded throughout experimentation and primary data analysis.
An electroanatomical map of the left ventricle (LV) was created using the NOGA
XP Cardiac Navigation System (Biosense Webster, Inc., Diamond Bar, CA). Cells
were injected by a single investigator blinded to infusate identity into the LV peri-
infarct region (border zone) (Figure 2) after verification of loop stability ,3 mm
and the presence of a ventricular premature contraction immediately upon needle
extrusion. Border zone was defined by a unipolar voltage of 6.9–10 mV upon
endocardial apposition of the catheter tip. Total cell dosage was divided into 10 to
15 injection sites, of ,150 ml per injection. Twenty-four hours later, the animal
was humanely euthanized and the heart, lung, liver, spleen, and kidney were
excised.
Ex vivo luciferase assay
Luciferase assay (depicted schematically in Supporting Image S1A) was performed
as described [30]. This method is advantageous because only viable cells can
generate a signal since the reaction requires transcription, translation, and ATP,
though possible false decreases in signal can occur due to gene silencing [31]. Cells
were transduced with an adenoviral vector carrying the firefly luciferase gene three
days prior to injection. For each animal, a separate standard curve was
constructed. Specifically, once the cell dose was allocated for injection, an aliquot
of cells (from the same batch of adenovirally-transduced cells used for that specific
pig) was cultured for an additional 24 hours to create the animal-specific standard
curve. Twenty four hours after cell delivery, the injected regions of the LV were
homogenized and analyzed for luminescence. We chose to analyze the totality of
the injected tissue (rather than isolated myocardial samples) to minimize
sampling error and accurately measure cardiac engraftment; however, this
approach prevented us from investigating the localization of the retained cells
(within the injected region) by immunohistochemistry. Animal-specific standard
curves were prepared by measuring the luminescence from known numbers of
transduced cells (Supporting Image S1B), with conversion to a cell number by
reference to the respective standard curve. Thus, transduction efficiency is equal in
the standard curve and in the cell products delivered, so that results for each
particular animal are not confounded. Twenty-four hour engraftment was
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expressed as a percentage of cells originally injected. Off-target engraftment of
cells in lung, spleen, liver, and kidney was similarly quantified. This validated
method has high sensitivity and reproducibility [26].
Dose Optimization Study
Cell Culture
A freshly-explanted heart from one male farm pig was cultured as above, with the
luciferase labeling step omitted, to generate secondary CSps; these were harvested
and filtered immediately prior to injection with a 160 mm nylon net to maintain a
uniform maximum size.
Induction of MI and transendocardial cell injection
Twenty four adult Yucatan minipigs (9¡2 months; 2 male, 22 female) weighing
44¡5 kg were studied. On day 0, animals underwent induction of MI by 100%
balloon occlusion of the mid-LAD for 2.5 hours, as described above. In the 4th
week post-MI, pigs were then re-anesthetized and received, by random
assignment: a) vehicle (PBS); b) low-dose CSps (15 million ICEs); c) high-dose
CSps (45 million ICEs), or; d) maximum feasible dose CSps (150 million ICEs).
An electroanatomical map of the LV was created and cells were injected as
described above (Figure 2) by a single investigator blinded to infusate identity.
Figure 2. NOGA-guided transendocardial injections. Left ventricular electroanatomic map created by the
NOGA XP Cardiac Navigation System. Red indicates scar tissue. Black dots indicate injection points into the
infarct border zone.
doi:10.1371/journal.pone.0113805.g002
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Figure 3. Cardiac percentage engraftment 24h post-injection. A) Comparison of cardiac engraftment
between all five doses of CDCs and CSps. Increasing doses of either cell type do not increase percentage
engraftment. However, since greater numbers of cells are being injected at higher doses, the absolute number
of engrafted cells increases with higher cell doses. B) Pooled CSps had significantly greater 24 h engraftment
than pooled CDCs (p50.036). C) There is little to no off-target engraftment (pooled CSps and CDCs, all
doses); cardiac engraftment is significantly higher than pulmonary engraftment (p,0.0001).
doi:10.1371/journal.pone.0113805.g003
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Vehicle/cells were divided into 15 injection sites of ,150 ml per injection. On
week 8, animals were re-anesthetized for euthanasia and heart explantation.
Cardiac MRI
To assess efficacy, baseline (just before intervention in the 4th week) and endpoint
(week 8) contrast-enhanced cardiac MRI was performed and analyzed by two
investigators blinded to treatment allocation, as described [30, 32], using the same
anesthetic protocol described above. Contrast-enhanced MRI has been shown to
accurately measure scarred and viable myocardium after cell therapy and therefore
represents an excellent tool for monitoring regenerative efficacy [32]. Animals
with LV ejection fraction (LVEF).50% at baseline were excluded from the
protocol and replaced (n54). This cutoff was chosen because normal LVEF in
minipigs is reported to be 54¡1.7% [33], indicating that minimal injury had
occurred if LVEF remained.50%. LVEF drops to 45.6¡10.4% one month post-
MI in the Yucatan minipig when infarct size is 10% or greater [34]. Total LV
mass, scar mass, scar size (scar mass4LV mass), viable myocardial mass (LV mass
minus scar mass), end-diastolic volume (EDV), end-systolic volume (ESV), LVEF,
and indices of regional function (end-systolic wall thickness, wall thickening, wall
motion) were measured.
Histocompatibility
Low-resolution swine leukocyte antigen typing was performed on the donor farm
pig and all recipient minipigs as described [35, 36] by a single investigator blinded
to treatment allocation. Divergent pig strains were used to simulate fully
allogeneic conditions in human transplantation where donor and recipient are
mismatched with regard to human leukocyte antigens (HLA).
Circulating anti-donor alloreactive antibodies
To evaluate humoral immune response, recipient pig serum was obtained at time
points t54 weeks (baseline) and 8 weeks (4 weeks post-injection). Serum was
screened with flow cytometry for circulating anti-donor IgG antibodies at both
time points. An allosensitization protocol was performed to provide controls for
comparison as described [37, 38]. Peripheral bone marrow mononuclear cells
(PBMMNCs) were harvested from a donor farm pig at four time points (t50, 7,
14, 21 days). Serum from the donor pig was tested for circulating anti-donor
antibodies at t50; this served as the negative control. PBMMNCs (190 million
cells divided into 4 doses and resuspended into injection volumes as indicated)
were resuspended and injected into the pinnae of recipient minipigs, n52. Two
intradermal (0.1 ml per injection) and two subcutaneous (1 ml per injection)
injections were administered to one minipig at t50, 7, 14 days. Two intradermal
(0.1 ml per injection) and two subcutaneous (1 ml per injection) injections were
administered to another minipig at t50, 21 days. Sera from minipigs were tested
for circulating anti-donor antibodies at four weeks post-injection; these served as
positive controls. Animals were humanely euthanized at endpoint.
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Histopathology
To evaluate possible immune responses in the heart, hematoxylin-and-eosin
staining was performed in sections obtained from the infarct (n53 slides per
heart), the injection sites (n56 slides per heart), and remote LV myocardium
(n53 slides per heart). Sections were analyzed by two independent pathologists
blinded to treatment allocation. Analysis was graded according to the
International Society for Heart & Lung Transplantation (ISHLT) guidelines, a
system used in clinical practice to grade cardiac allograft rejection [39]. Additional
histopathology features were assessed, including amount of calcification,
granulation tissue, and necrosis. To measure myocyte cross-sectional area,
sections obtained from the infarct border zone underwent immunostaining for
troponin I (Abcam, Cambridge, MA) and wheat-germ agglutinin (Molecular
Probes, Grand Island, NY) (to visualize cell borders); Alexa Fluor conjugated
secondary antibodies (Molecular Probes) were used and counterstaining with
DAPI (Molecular Probes) was performed. Sections were imaged using a confocal
laser scan microscope (Leica Microsystems, Buffalo Grove, IL) and images were
processed by Leica Application Suite software.
Pivotal study
Cell culture
A freshly-explanted heart from one male farm pig was cultured as above, with the
luciferase labeling step omitted, for generation of secondary CSps, which were
harvested and suspended in CryoStor CS10 (BioLife Solutions, Bothell, WA) at a
per animal dose of 150 million ICEs. CSps were frozen and stored at 280 C̊. Cells
were thawed and filtered immediately prior to injection with a 160 mm nylon net
filter to maintain a uniform maximum size.
Induction of MI and transendocardial cell injection
Twenty nine adult Yucatan minipigs (10¡2 months; 14 male, 15 female)
weighing 44¡6 kg were studied. On day 0, minipigs underwent induction of MI
by 100% occlusion of the mid-LAD for 3 hours, as described above. Eight weeks
post-MI, minipigs received by random assignment: a) vehicle (CryoStor CS10); or
b) CSps (150 million ICEs). An electroanatomical map of the LV was created and
cells were injected as described above (Figure 2) by a single investigator blinded to
treatment allocation, into 15 injection sites of 150 ml per injection. Eight weeks
after injection, an electrophysiology study was performed (see Electrophysiology
Study below); animals then underwent humane euthanasia, followed by
explantation of the heart, brain, liver, kidneys, lungs, and spleen. In order to
create a more clinically-realistic model of advanced chronic ischemic cardio-
myopathy, a longer ischemia time (3 hours vs 2.5 hours), a later time-point of cell
injection (8 weeks vs 3–4 weeks) and a longer follow-up (8 weeks vs 4 weeks) were
used in the pivotal study compared to the dose optimization study.
Transendocardial Allogeneic Cardiospheres in Pigs
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Cardiac MRI
To assess efficacy, baseline (8 weeks post-MI, before transendocardial injections)
and endpoint (8 weeks post-injection) contrast-enhanced cardiac MRI was
performed, as described above [32]. Animals with LVEF.50% at baseline were
excluded from the protocol and replaced (n53). MRIs were analyzed by an
investigator blinded to treatment allocation. Scar mass, scar size, viable
myocardium, total LV mass, LVEF, EDV, ESV, and indices of regional function
(end-systolic wall thickness, wall thickening, wall motion) were measured.
Electrophysiology Study
To assess the inducibility of ventricular arrhythmias, an electrophysiology study
with provocative testing was performed at t516 weeks. Programmed electrical
stimulation of the right ventricle was performed as described [40]. In brief, eight
ventricular drive beats (pacing cycle length 250 ms) were delivered. The first extra
stimulus (S2) was set at 230 ms after the last pacing stimulus of the drive train
(S1). S2 was progressively shortened in 10 ms decrements until the effective
refractory period was reached. If no arrhythmia was induced, additional extra
stimuli were introduced 170–200 ms after the previous extra stimulus.
Inducibility of ventricular arrhythmias was recorded in a binary fashion.
Bloodwork
Complete blood count, chemistry panel, creatine kinase-MB (CKMB), cardiac
troponin I (cTnI), C-reactive protein (CRP), and erythrocyte sedimentation rate
(ESR) were analyzed at time points t50, 8 weeks (pre- and post-injection), 10
weeks, 16 weeks.
Atrial Natriuretic Peptide measurements
Venous blood was collected 8 and 16 weeks post-MI. Plasma levels of porcine a-
ANP, which is similar to the human peptide [41, 42], were analyzed by two
investigators blinded to treatment allocation. Venous blood was transferred to test
tubes containing potassium EDTA (1.8 mg/mL). After gently mixing for 1 min,
blood was centrifuged at 4 C̊ and plasma was frozen and stored at 280 C̊ until
assay. Stored plasma was thawed, diluted with an equal volume of saline
containing 40 mM HCl on ice, and centrifuged at 13,0006 g at 4 C̊ for 15 min.
The resulting supernatant was loaded onto a Sep-Pak Plus C18 cartridge (Waters,
Milford, MA, USA) that was prewashed sequentially with 5 mL each of
chloroform and methanol, 15 mL each of 50% acetonitrile containing 0.1%
trifluoroacetic acid (TFA), 0.1% TFA, and saline. After washing with 10 mL each
of saline, 0.1% TFA, and 20% acetonitrile containing 0.1% TFA, the absorbed
materials were eluted with 5 mL of 50% acetonitrile containing 0.1% TFA and
lyophilized, as previously described [43]. The plasma extract was dissolved in
500 mL of radioimmunoassay (RIA) standard buffer, and a 100 mL aliquot of each
sample was used for RIA. ANP is highly conserved among mammalian species
[41]. The RIA used detects both porcine a-ANP and human a-ANP [44], and was
performed using antiserum #125-8 at a final dilution of 400,000 [44]. A 50%
Transendocardial Allogeneic Cardiospheres in Pigs
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inhibition value of tracer binding (IC50) was 10 fmol/tube, and a-ANP level was
quantitatively measurable in a range of 1.0–100 fmol/tube.
Histocompatibility
Low-resolution swine leukocyte antigen typing was performed on the donor farm
pig and all recipient minipigs as described above in the dose optimization Study.
Circulating anti-donor alloreactive antibodies
To evaluate humoral immune response, recipient pig serum was obtained at t58
weeks (prior to injection), 10 weeks and 16 weeks post-MI. Serum was screened
with flow cytometry for circulating anti-donor IgG antibodies at all three time
points by a single investigator blinded to treatment allocation. The allosensitiza-
tion protocol described above in the dose optimization study provided positive
and negative controls for comparison.
Histopathology
To evaluate immune responses in the heart, hematoxylin-and-eosin staining was
performed in sections obtained from the infarct (n53 slides per heart), border
zone (n56 slides per heart), remote myocardium within the LV (n53 slides per
heart), left atrium (n51 slide per heart), right atrium (n51 slide per heart), and
right ventricle (n51 slide per heart), as described above in the dose optimization
study. Myocyte cross-sectional area was also analyzed as described above.
Statistical analysis
Data are expressed as mean ¡ SD. Data were compared using paired t-test,
independent t-test, Fisher’s exact test, or ANOVA using a Bonferroni correction
when applicable (SPSS Statistics 17.0, Chicago, IL). p,0.05 was considered
statistically significant.
Results
Adverse events and mortality
In the engraftment study, 22/33 animals (67%) survived the initial MI and were
included for analysis. There was no further mortality within the protocol, nor
were there any adverse events.
In the dose optimization study, 16/24 animals (67%) with a baseline
LVEF#50% survived the initial MI and were included for analysis. There was no
further mortality, nor were there any adverse events during the initial injection
procedure in either group. One pig in the placebo group went into ventricular
fibrillation during the endpoint electromechanical mapping procedure and was
rapidly defibrillated with no other adverse events.
In the pivotal study, 22/29 animals (76%) with a baseline LVEF#50% survived
the initial MI and were included for analysis. There was no further mortality in
these pigs. During the injection procedure, one pig in the placebo group went into
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ventricular fibrillation; the animal was defibrillated and completed the study with
no further adverse events. One pig in the placebo group went into ventricular
fibrillation during the endpoint electromechanical mapping procedure and was
defibrillated with no other adverse events.
In the allosensitization study, there were no adverse events (0 of 3).
Compatibility of CSps with the injection catheter
At concentrations >133 million ICEs in the form of CSps per ml, the injection
solution was excessively viscous, precluding passage through the needle
(Supporting Image S2). At all concentrations less than 133 million ICEs in the
form of CSps per ml, cell viability was maintained (,86% remain viable) after
passage through the 27 g catheter needle. An isolated cell equivalent (ICE) is
defined as the absolute number of cells in an aliquot of CSps. CSps are quantified
as ICEs because any given cardiosphere is an aggregate that consists of a variable
number of cells. In order to accurately quantify actual cell numbers, CSps are thus
separated into the individual cells that make them up, then counted. Assuming an
injection volume of 150 ml, a dose of 20 million ICEs as CSps per injection is the
maximum which can be reliably resuspended. Due to the considerable time and
resource constraints necessary for culturing this dose (300 million ICEs in the
form of CSps per animal, delivered in 15 injections), our maximum feasible dose
was set to 10 million ICEs in the form of CSps per injection (i.e., 150 million ICEs
in the form of CSps per animal). The Myostar injection catheter is equipped with
a 27 g needle (internal diameter of 210 mm) [45]. Porcine CSps can grow up to
200 mm in diameter [26]; ours were filtered to a maximum size of 160 mm. CSp
size (Supporting Image S3) and viability (Supporting Image S2) were not
compromised by passing through the injection catheter in the dose range tested.
Histocompatibility
SLA haplotypes revealed complete Class I (SLA-1, SLA-2, SLA-3) and Class II
(DRB1, DQB1, DQA) mismatches between the donor pig and all recipients in the
dose optimization (Supporting Image S4) and pivotal (Supporting Image S5)
studies.
Engraftment Study
Transendocardial injection of heart-derived cells resulted in robust cardiac
retention, with minimal off-target engraftment (Figure 3). Twenty-four hour
cardiac engraftment for 5 million CDCs was 13.9¡4.9% (n54); 10 million CDCs
was 13.3¡4.0% (n54); 5 million ICEs delivered as CSps was 19.5¡8.6% (n54);
10 million ICEs delivered as CSps was 18.0¡4.6% (n54); and 100–200 million
ICEs delivered as CSps was 17.5¡1.9% (n56). There was no difference in
percentage engraftment with increasing doses of CDCs (p50.87) or CSps
(p50.84), nor was there any difference in percentage engraftment among the five
groups (p50.34) (Figure 3A). However, 24 hour engraftment of pooled CSps
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(18.2¡4.9%) was greater than that of CDCs (13.6¡4.1%) (p50.036) (
Figure 3B). Due to their superior percentage engraftment, we chose CSps for the
dose-ranging study. There was minimal off-target engraftment of heart-derived
cells (CSps and CDCs, 5–2006106 cells) in the lungs (0.7¡1.7%), liver (0%),
spleen (0%), or kidneys (0%) (Figure 3C).
Dose Optimization Study
Safety
Blinded histopathological analysis revealed increased focal lymphoplasmacytic
infiltration (Grade 1R) in the injection sites of minipigs injected with allogeneic
CSps compared to those with placebo (Figure 4A–C). However, the incidence of
Figure 4. Immune response in the dose optimization study. A) After meticulous sampling of all heart sections, including the injection sites at the infarct
border zone, this slide represents the worst case of immune reaction seen in all injected pigs in the dose optimization study. A lymphoplasmacytic cellular
infiltration is observed near the injection site. B) High power image of boxed area in (A). C) Number of animals in dose optimization study showing Grade 0R
(light pink) or 1R (red) histopathology in remote myocardium and injection sites. D) No circulating anti-donor antibodies could be detected in pigs that were
transendocardially injected with allogeneic CSps at baseline and 4 weeks post-injection in the dose optimization study. High titers of circulating anti-donor
antibodies were detected in minipigs 4 weeks post PBMMNC injection (subcutaneous and intradermal injections) that served as positive controls of
allosensitization.
doi:10.1371/journal.pone.0113805.g004
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Grade 1R histopathology was not dose-dependent. The infiltrating cells were
localized within interstitial and perivascular spaces (Figure 4A,B); importantly, no
foci of myocyte damage were detected. The remote myocardium was consistently
clear of infiltrating inflammatory cells. Interestingly, there was a dose-dependent
Table 1. Summary of dose optimization MRI data by dose group.
MRI Index Dose Baseline Endpoint Paired t-test
(t54 wk) (t58 wk) p value
Scar mass (g) Placebo 8.3¡0.8 8.5¡1.3 ns
15 mill CSps 8.8¡1.9 8.6¡2.9 ns
45 mill CSps 7.9¡2.9 7.0¡3.1 0.023
150mill CSps 10.0¡2.2 8.4¡1.3 ns
Scar size (% of LV) Placebo 11.6¡1.7 12.3¡2.9 ns
15 mill CSps 12.0¡3.9 11.0¡3.8 ns
45 mill CSps 12.0¡3.6 10.1¡3.5 ,0.001
150mill CSps 13.4¡1.8 10.3¡1.8 0.043
Viable myocardium (g) Placebo 63.6¡5.3 60.9¡8.0 ns
15 mill CSps 70.4¡12.2 72.2¡6.3 ns
45 mill CSps 58.0¡5.3 62.4¡5.9 ns
150mill CSps 64.3¡7.3 74.8¡11.8 0.038
LV mass (g) Placebo 71.9¡4.7 69.4¡7.2 ns
15 mill CSps 79.2¡11.4 80.8¡5.9 ns
45 mill CSps 65.9¡7.8 69.3¡8.8 ns
150mill CSps 74.3¡8.9 83.2¡12.2 0.039
LVEF (%) Placebo 47.6¡2.4 42.9¡2.4 0.002
15 mill CSps 43.7¡5.8 41.7¡5.6 0.024
45 mill CSps 45.2¡3.1 44.0¡4.8 ns
150mill CSps 47.5¡3.0 48.6¡1.8 ns
EDV (ml) Placebo 71.1¡10.2 79.6¡10.5 ns
15 mill CSps 81.2¡11.0 88.6¡13.7 ns
45 mill CSps 65.8¡14.4 74.1¡12.6 ns
150mill CSps 73.2¡5.8 79.6¡11.4 ns
ESV (ml) Placebo 37.4¡6.0 45.6¡7.7 0.015
15 mill CSps 45.7¡7.5 51.3¡6.8 ns
45 mill CSps 36.2¡8.9 41.7¡9.0 ns
150mill CSps 38.4¡1.8 40.9¡5.4 ns
Body Weight Gain (kg) Placebo n/a 6.6¡1.9 ns (ANOVA & Ind t-test)
15 mill CSps n/a 8.1¡3.0
45 mill CSps n/a 6.5¡2.9
150mill CSps n/a 8.1¡2.2
HR during MRI (bpm) Placebo n/a 119¡10 ns (ANOVA & Ind t-test)
15 mill CSps n/a 109¡17
45 mill CSps n/a 111¡15
150mill CSps n/a 108¡13
doi:10.1371/journal.pone.0113805.t001
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decrease in the amount of mineralization (calcium deposition) and granuloma-
tous inflammation in CSp-injected animals compared to placebo. There were no
other histologically-significant differences between CSp-injected and placebo-
injected animals.
With regard to humoral memory response, no alloreactive antibodies were
detected in any recipients of allogeneic CSps at any time point. In contrast, in the
sensitized minipigs used as positive controls, high titers of circulating alloreactive
IgG antibodies were detected four weeks post-injection (Figure 4D).
Representative flow cytometry histograms are provided in Supporting Image S6.
Efficacy
To assess efficacy, minipigs underwent MRI before transplantation and four weeks
later. Absolute values for MRI-measured parameters are displayed in Tables 1 & 2.
Individual animal MRI indices are plotted in Supporting Image S7. All CSp doses
attenuated remodeling; ESV increased in the control group (p50.015) but was
preserved in all CSp groups (p5ns) (Table 1). The two higher CSp doses (45 &
150 million ICEs delivered as CSps) were effective in preserving LVEF (Figure 5A).
No differences in regional function (systolic thickening, end-systolic thickness,
and wall motion) of infarcted segments were observed between groups (Table 2).
In terms of regenerative efficacy, the key parameters are viable myocardial mass
and scar size [6]. Figure 6 shows representative images from a control animal
(A,B) and a CSp-treated animal (C,D) at baseline (A,C) and 4 weeks later (B,D).
The scar is hyperenhanced (white), while viable myocardium appears black. In the
control animal (A,B), the scar does not become smaller over time, nor does the
amount of viable myocardium appear to increase. In contrast, the CSp-treated
heart (C,D) visibly undergoes scar shrinkage as well as an increase in viable mass
over the month after treatment. Data such as these, when analyzed volumetrically
and pooled, yield the average results plotted in Figures 5B (change in scar size)
and 5C (change in viable myocardial mass). While increasing CSp doses led to
Table 2. Summary of dose optimization MRI data by dose group.
MRI Index Dose Endpoint (t58 wk) p value (ANOVA)
Wall thickness (mm) Placebo 6.2¡1.2 ns
15 mill CSps 6.0¡2.4 ns
45 mill CSps 5.2¡1.7 ns
150mill CSps 6.0¡1.2 ns
Wall thickening (%) Placebo 14.7¡33.8 ns
15 mill CSps 22.3¡22.3 ns
45 mill CSps 7.8¡25.9 ns
150mill CSps 11.5¡27.1 ns
Wall motion (mm) Placebo 2.1¡1.3 ns
15 mill CSps 2.7¡1.5 ns
45 mill CSps 2.1¡1.6 ns
150mill CSps 2.3¡1.5 ns
doi:10.1371/journal.pone.0113805.t002
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Figure 5. Dose-dependent functional and structural benefits after catheter-guided transendocardial
injection of allogeneic CSps in dose optimization study. A) Comparison of LVEF treatment effect in all 4
dose optimization groups. B) Comparison of scar size treatment effect in all 4 dose optimization groups. C)
Comparison of viable myocardial mass treatment effect in all 4 dose optimization groups.
doi:10.1371/journal.pone.0113805.g005
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progressively greater improvement, the 150 million CSp dose was superior in
increasing viable myocardium (Figure 5C) and in reducing scar size (Figure 5B),
and was thus chosen for further testing in our pivotal study (see below).
An increase in viable myocardium by MRI may reflect either more myocytes
(regeneration) or larger myocytes (hypertrophy) [32]. Cardiomyocyte cross-
sectional area was similar in CSp-treated minipigs and controls (Figure 7B), thus
excluding hypertrophy as a contributor to the increase in viable myocardium
observed after cell therapy.
Pivotal Study
Safety
Blinded histopathological analysis revealed no abnormalities in the brain, kidneys,
liver, lung, or spleen related to heart-derived cell injection. In contrast to the dose
optimization study, cardiac histopathology did not reveal increased lymphoplas-
macytic infiltration in the border zone of minipigs injected with allogeneic CSps 8
weeks post-injection (Figure 8A). This difference may be attributed to a transient
mononuclear infiltration that, while detectable one month post-injection
(endpoint of the dose optimization study), had fully resolved by 8 weeks post-
injection (endpoint of the pivotal study). No foci of inflammation-associated
myocyte damage were detected. There was a decreased occurrence of
mineralization/calcium deposition and granulomatous inflammation in cell-
treated animals, similar to what was observed in the dose optimization study.
With regard to a humoral memory response, no alloreactive antibodies were
detected in any recipients of allogeneic CSps at any time point (Figure 8B).
Figure 6. Myocardial regeneration after catheter-guided transendocardial injection of allogeneic CSps
in dose optimization Study. Representative short-axis slices of contrast-enhanced cardiac MRIs at baseline
(left) and 4 weeks later (right) in a control pig (top row) and a CSp-treated pig (45 million ICEs delivered as
CSps; lower row). Infarct scar tissue is evident by areas of hyperintensity (white) whereas viable myocardium
appears dark. Arrows point to infarct scar.
doi:10.1371/journal.pone.0113805.g006
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Figure 7. Myocyte cross-sectional area. A) Representative section showing cardiomyocyte cross-sectional
area at infarct border zone (injection site). B) Dose optimization study cross-sectional area was measured and
compared, showing similar myocyte sizes across all 4 groups (p5ns). C) Pivotal study cross-sectional area
was measured and compared, showing similar myocyte sizes in placebo and cell-treated groups (p5ns).
doi:10.1371/journal.pone.0113805.g007
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Comparisons of 39 blood parameters showed no significant differences in any
inflammatory or immunological markers (total white blood cell count, CRP, ESR)
or injury-related markers (cTnI, CKMB) at all time-points. Endpoint neutrophil
count was significantly higher in cell-treated animals; however, this was due to
one outlier pig who suffered a forelimb lameness during the study. All other
animals in the cell-treated group had a neutrophil count within normal limits.
Figure 8. Immune response in the pivotal study. A) Number of animals in pivotal study showing Grade 0R (light pink) or 1R (red) histopathology in remote
myocardium and injection sites. B) No circulating anti-donor antibodies could be detected in pigs that were transendocardially injected with allogeneic CSps
2 or 8 weeks post-injection in the pivotal study. High titers of circulating anti-donor antibodies were detected in minipigs 4 weeks post PBMMNC injection
(subcutaneous and intradermal injections) that served as positive controls of allosensitization.
doi:10.1371/journal.pone.0113805.g008
Table 3. Summary of pivotal study MRI data by dose group.
MRI Index Treatment Baseline (t58 wk) Endpoint (t516 wk) Paired t-test p value
Scar mass (g) Placebo 6.1¡1.9 7.2¡2.4 ,0.001
CSps 6.7¡3.1 6.4¡2.6 ns
Scar size (% of LV) Placebo 10.9¡2.3 11.5¡2.4 0.026
CSps 11.1¡3.2 9.5¡2.7 ,0.001
Viable myocardium (g) Placebo 50.0¡6.3 54.7¡6.5 ,0.001
CSps 51.9¡6.8 60.0¡6.9 ,0.001
LV mass (g) Placebo 56.1¡7.6 61.9¡8.1 ,0.001
CSps 58.6¡9.2 66.4¡8.9 ,0.001
LVEF (%) Placebo 42.1¡7.0 40.9¡7.7 ns
CSps 43.6¡5.2 43.2¡5.1 ns
EDV (ml) Placebo 80.8¡21.7 93.2¡20.1 0.001
CSps 81.7¡15.5 89.0¡23.5 ns
ESV (ml) Placebo 48.0¡18.3 56.3¡19.3 0.002
CSps 46.7¡13.6 51.5¡19.7 Ns
Body weight gain (kg) Placebo n/a +12.5¡3.8 ns (Ind t-test)
CSps n/a +14.0¡4.7
HR during MRI (bpm) Placebo n/a 112¡13 ns (Ind-t-test)
CSps n/a 99¡18
doi:10.1371/journal.pone.0113805.t003
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As in our previous porcine studies [26, 30], all animals in both groups exhibited
inducible arrhythmias at endpoint, with no difference between placebo and cell-
treated groups.
Efficacy
To assess efficacy, minipigs underwent MRI before CSp transplantation and eight
weeks later. MRIs were analyzed in a blinded manner; results are displayed in
Tables 3 & 4. Individual animal MRI indices are plotted in Supporting Image S7.
No significant improvement in global (LVEF) (Figure 9E) or regional (systolic
thickening, end-systolic thickness, wall motion) LV function could be observed in
cell-treated animals compared to controls (Table 4). The fact that EF in control
pigs in the pivotal study remained relatively stable over the follow-up period
(between weeks 8–16 post-MI), while it decreased in control pigs in the dose-
response study (between weeks 3–7 post-MI) is consistent with the natural history
of porcine ischemic cardiomyopathy; EF drops in the first weeks post-MI and
remains relatively stable thereafter [28, 29, 46]. Despite the lack of an effect of cell
therapy on EF in this protocol, minipigs treated with allogeneic CSps displayed
attenuation of structural adverse remodeling. EDV and ESV increased
significantly in the placebo group but not in the CSp group over the 8 week
follow-up (Figure 9C,D). In addition, while plasma ANP increased in the placebo
arm between baseline and endpoint, ANP levels remained stable in cell-treated
pigs. This finding supports the global hemodynamic significance of the observed
attenuation of LV remodeling (Figure 9F).
In terms of regenerative efficacy, CSp-treated animals benefited from a
significant increase in viable myocardium (Figure 9B) and concomitant decrease
in scar size compared to placebo (Figure 9A). Importantly, cardiomyocyte cross-
sectional area was similar in CSp-treated minipigs and controls (Figure 7C),
excluding hypertrophy as a contributor to the increase in viable myocardium
observed after cell therapy.
Discussion
We have tested, systematically, the feasibility, safety and efficacy of percutaneous
intramyocardial delivery of heart-derived cells. We first optimized dosing and
Table 4. Summary of pivotal study MRI data by dose group.
MRI Index Treatment Endpoint (t516 wk) p value (Ind t-test)
Wall thickness (mm) Placebo 4.2¡1.6 ns
CSps 4.6¡2.3 ns
Wall thickening (%) Placebo 12.6¡23.1 ns
CSps 10.9¡26.0 ns
Wall motion (mm) Placebo 2.2¡1.4 ns
CSps 2.3¡1.7 ns
doi:10.1371/journal.pone.0113805.t004
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Figure 9. Dose-optimized transendocardial injection of allogeneic CSps in the pivotal study attenuated remodeling, decreased scar size and
increased viable myocardium in a porcine model of chronic ischemic cardiomyopathy. A) Comparison of scar size treatment effect in both placebo
and cell-treated pivotal study groups. B) Comparison of viable myocardium treatment effect in both placebo and cell-treated pivotal study groups. C) End-
diastolic volume measurements at baseline and 8 weeks post-injection in both placebo and cell-treated pivotal study groups. D) End-systolic volume
measurements at baseline and 8 weeks post-injection in both placebo and cell-treated pivotal study groups. E) Comparison of LVEF treatment effect in both
placebo and cell-treated pivotal study groups. F) Comparison of plasma ANP treatment effect in both placebo and cell-treated pivotal study groups.
doi:10.1371/journal.pone.0113805.g009
Transendocardial Allogeneic Cardiospheres in Pigs
PLOS ONE | DOI:10.1371/journal.pone.0113805 December 2, 2014 21 / 29
delivery protocols for catheter-guided transendocardial injections. We then tested
the safety and efficacy of allogeneic CSps in a clinically-relevant large animal
model of chronic ischemic cardiomyopathy. The salient findings are:
1) Catheter-guided delivery of heart-derived cell products produces robust
cardiac engraftment, with minimal off-target engraftment. While escalating
doses of CSps and CDCs do not affect percentage engraftment, injection of
CSps results in more robust percentage engraftment compared to CDCs.
2) Delivery of allogeneic CSps is safe, inducing a transient, mild local immune
response with no signs of systemic immunogenicity or toxicity.
3) Dose-optimized allogeneic CSp injection produces functional benefits and
therapeutic regeneration in a porcine model of chronic ischemic cardiomyo-
pathy.
While most cell therapy studies to date have focused on intracoronary delivery
in acute or convalescent MI patients [22], chronic ischemic cardiomyopathy
patients represent a growing target population. The chronic setting is likely more
difficult to treat with cell therapy because adverse cardiac remodeling has already
progressed, and local homing signals are reduced [16]. These attenuating factors
might, in principle, be counteracted by more effective and targeted delivery of
cells. To that end, intramyocardial delivery has been shown to result in higher
cardiac retention compared to intracoronary or systemic approaches, while
implementation of electromechanical mapping enables targeted delivery of cells to
viable myocardium in the border zone of chronic scars. In addition, in the vast
majority of preclinical and clinical studies of transendocardial delivery of cell
types grown from other organs, dosing has not been systematic; instead, it has
been guided by feasibility and accessibility rather than purposeful optimization.
Here, we demonstrate that percutaneous transendocardial delivery of heart-
derived cell products in the infarct border zone results in robust cardiac
engraftment of up to 20%, higher than with any other previously-reported
delivery method [3]. CSps outperform other stem cell types, where 24 hour
engraftment is generally ,10%, regardless of delivery route [13]. Injection of
CSps results in more robust short-term engraftment compared to CDCs. The
latter may be attributable to the larger size of CSps (allowing for greater passive
entrapment of CSps within the myocardium), as well as to upregulation of
adhesion molecules on the CSp surface [25].
CSps are self-organized spherical clusters of heart-derived cells, characterized by
increased stemness [25]. Due to their larger size of 40–150 mm, CSps may not be
safe to administer intracoronarily, as they would likely embolize in the
microvasculature. In previous reports, we showed that IM delivery of CSps
disproportionately boosts cardiac function in small and large animal models of
ischemic cardiomyopathy compared with monolayer-cultured CDCs [25, 26].
We have also shown that injection of allogeneic CDCs and CSps in a stringent
rat model of allotransplantation post-MI is safe, inducing a transient local
immune response [47, 48]. Allogeneic cell therapy is desirable because it
circumvents the logistic, economic, and timing constraints associated with
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autologous cell therapy. It also enables a highly-standardized off-the-shelf product
to be generated from a universal donor pool. Here we show that transendocardial
injection of allogeneic CSps in a large-animal model of chronic ischemic
cardiomyopathy induces a mild local immune response with no signs of systemic
immunogenicity or toxicity. No circulating anti-donor antibodies were detected
in any of the treated pigs, giving reason for optimism with regard to the
immunogenicity of allogeneic CSps in humans. The latter is important since
patients with advanced ischemic cardiomyopathy may also be candidates for solid
organ transplantation, such that highly-immunogenic agents are best avoided.
By design, the dose optimization study preceded the pivotal study. Because the
two studies were not performed contemporaneously, direct comparison of the
outcome is not straightforward. Nevertheless, the beneficial effects of cardio-
spheres appear to be blunted in the pivotal study in comparison to the dose
optimization study. The benefits may genuinely be more pronounced with
treatment 4 weeks post-MI than 8 weeks post-MI: intervention in the early phases
of remodeling and infarct healing may be more effective compared to intervention
after healing is complete, but this possibility remains conjectural. EF drops in the
first weeks post-MI and remains relatively stable thereafter [28, 29, 46]. There is a
minimal, albeit detectable, decline in EF that occurs between 4 and 12 weeks post-
MI, where increased myocardial fibrosis is present [49]. This may blunt the effects
of cell therapy, though intervention up to 8 weeks post-MI may still be beneficial
in myocardial regeneration, as evidenced by the present study. Xiong et al [50]
recently studied human induced pluripotent stem cells in an acute infarct model
with a 4 week followup period. Even though the Xiong model is different, our
outcomes appear to be at least as effective, and sometimes even better, in
improving infarct size. Interestingly, the LVEF in Xiong et al increased by
approximately +6% in both the placebo and cell-treated arms between 1 and 4
weeks post-MI, while in our study, the LVEF fell in the placebo arm of both the
dose optimization and pivotal studies (approximately 25% and 22%,
respectively), while increasing or staying the same in the 150M dose treated arms
(approximately +1% and +0%, respectively). Moreover, the animal model used by
Xiong et al used juvenile Yorkshire swine whose cardiac physiology may differ
from those of older minipigs [51, 52]. Lastly, the animals in the paper by Xiong et
al were immunosuppressed, unlike those in our study.
Finally, we show that dose-optimized percutaneous transendocardial injection
of allogeneic CSps, tested in a randomized, blinded, placebo-controlled manner,
attenuates remodeling, decreases scar size and increases viable myocardium. CSps
are rich in matrix metalloproteinases [26], which could contribute to dissolution
of scar tissue. The increase in viable myocardium did not result from myocyte
hypertrophy, and likely occurs through stimulation of endogenous protective
(anti-apoptotic), and regenerative mechanisms (upregulation of cardiomyocyte
cycling, increased recruitment of endogenous stem cells [47, 53, 54, 55, 56]). The
decreases in scar size, mirrored by increases in viable myocardium, resemble the
changes seen in human subjects treated with CDCs [6] and are indicative of
therapeutic regeneration. It should be noted that we observed greater benefits,
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especially with regard to EF, in the dose optimization study when CSps were
injected 3–4 weeks post-MI, compared to the pivotal study where CSps were
injected 8 weeks post-MI. Whether this means that cell therapy is more effective in
the setting of convalescent MI compared to chronic ischemic cardiomyopathy
remains to be further investigated.
Limitations
Our study has several limitations. First, we only quantified 24 hour cardiac
retention but not long-term engraftment. However, long-term engraftment is
vanishingly low regardless of delivery method [4]; early cardiac cell retention
appears to be a better predictor of long-term functional benefit [11, 12, 13].
Second, while we measured total 24 hour cardiac engraftment, we did not
investigate the distribution of the transplanted cells within the host myocardium.
While luciferase might conceivably be measured from nonviable cells, this is
unlikely given the short 3 hour half-life of luciferase and the requirement for ATP
[57]. Third, our study does not provide any mechanistic insight into the
regenerative effects of CSps. Fourth, we have not thoroughly validated the use of
MRI to assess therapeutic regeneration after CSp IM injection, as we have done
with CDC intracoronary delivery [32]. However, the similarity between the two
cell products with regard to mechanism of action [25] gives some reassurance that
MRIs will be similarly interpretable in the current protocols. Fifth, as with all
animal studies, there is the potential that the increase in LV mass in each of the
chronic MI groups could be confounded by growth of the animal; however, if this
were the case then all parameters should be similarly and linearly changed. Finally,
the normal range of porcine-ANP has not been established, nor did we measure
porcine-ANP in normal minipigs. Therefore, we are only able to assay relative
changes within the two groups (CSp vs placebo) from baseline to endpoint.
Conclusions
Transendocardial injection of heart-derived cell products results in robust short-term
cardiac engraftment (better with CSps than CDCs). Delivery of allogeneic CSps is safe,
inducing a transient, mild local immune response with no signs of systemic
immunogenicity or toxicity. Dose-optimized injection of CSps attenuates cardiac
dilatation, decreases scar size, and increases viable myocardium. The increases in viable
myocardium, mirrored by decreases in scar, are consistent with genuine regeneration.
Supporting Information
Supporting Image S1. Ex vivo luciferase assay. A) Timeline of steps in performing
ex vivo luciferase assay. B) Representative standard curve created by measuring
luciferase signal from known numbers of transduced cells.
doi:10.1371/journal.pone.0113805.s001 (TIF)
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Supporting Image S2. Determination of maximal feasible dose. Cells were dosed
on a per pig basis. Total injection volume was predetermined at 1.5 ml (150 ml per
injection 610 injections). Viability and cell number were compared before and
after injection through the Myostar injection catheter. At doses higher than 133
million ICEs delivered as CSps/ml, the solution could not be extruded through the
injection catheter.
doi:10.1371/journal.pone.0113805.s002 (TIF)
Supporting Image S3. Size distribution of CSps. Porcine cells were qualitatively
analyzed for size distribution, both pre- and post-injection through the Myostar
catheter. Size distribution of cells remained similar pre- and post-injection,
indicating that CSp clusters remained intact during passage through the catheter.
doi:10.1371/journal.pone.0113805.s003 (TIF)
Supporting Image S4. Summary of SLA haplotype mismatches between stem cell
donor farm pig and each recipient minipig in dose optimization study. Donor pig
inferred low-resolution SLA haplotype is Lr-26.23/26.23 [35, 36].
doi:10.1371/journal.pone.0113805.s004 (TIF)
Supporting Image S5. Summary of SLA haplotype mismatches between stem cell
donor farm pig and each recipient minipig in pivotal study. Donor pig inferred
low-resolution SLA haplotype is Lr-35.12/35.23.
doi:10.1371/journal.pone.0113805.s005 (TIF)
Supporting Image S6. Assessment of humoral memory response in pivotal study.
Levels of circulating IgG anti-donor antibodies were measured in pig serum
samples with flow cytometry. A) High titers of circulating anti-donor antibodies
were detected in minipigs 4 weeks post PBMMNC injection (subcutaneous and
intradermal injections) that served as positive controls with allosensitization. B)
Representative sample of cell-injected pig. No circulating anti-donor antibodies
could be detected in any pigs that were transendocardially injected with allogeneic
CSps or placebo.
doi:10.1371/journal.pone.0113805.s006 (TIF)
Supporting Image S7. Individual animal MRI data from both dose optimization
and pivotal studies, plotted together. Error bars show 95% confidence interval.
Time points are given as number of weeks post-MI. A) Scar size decreases with cell
injection and increases with placebo in both the dose optimization and pivotal
studies. B) Viable left ventricular mass increases with cell injection and decreases
with placebo in the dose optimization study. Viable left ventricular mass increases
with both cell injection and placebo in the pivotal study, though the increase is
less dramatic with placebo. C) End diastolic volume increases with both cell
injection and placebo. In the pivotal study, endpoint EDV increases significantly
with placebo only, while EDV increases non-significantly with cell injection,
corresponding with preservation of left ventricular remodeling. D) End systolic
volume increases with both cell injection and placebo. In both the dose
optimization and pivotal studies, endpoint ESV increases significantly in placebo
while cell injection maintains ESV, corresponding with preservation of left
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ventricular remodeling. E) Left ventricular ejection fraction decreases with
placebo in both the dose optimization and pivotal studies; the decrease is
significant in the dose optimization study. Ejection fraction increases non-
significantly with cell injection in the dose optimization study and decreases non-
significantly with cell injection in the pivotal study.
doi:10.1371/journal.pone.0113805.s007 (TIF)
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